These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 26556035

  • 21. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, Mohanty AS, Cheng DT, Berger MF, Soslow RA, Weigelt B.
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [Abstract] [Full Text] [Related]

  • 22. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N, Manrai P, Rottmann D, Wu X, Assem H, Hui P, Buza N.
    Int J Gynecol Pathol; 2023 Nov 01; 42(6):567-575. PubMed ID: 36730675
    [Abstract] [Full Text] [Related]

  • 23. Pathology of Endometrial Carcinoma.
    Lax SF.
    Adv Exp Med Biol; 2017 Nov 01; 943():75-96. PubMed ID: 27910065
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM, Patterson NE, Gressel GM, Karabakhtsian RG, Bejerano-Sagie M, Ravi N, Maslov A, Quispe-Tintaya W, Wang T, Lin J, Smith HO, Goldberg GL, Kuo DYS, Montagna C.
    BMC Med Genomics; 2020 Nov 30; 13(1):179. PubMed ID: 33256706
    [Abstract] [Full Text] [Related]

  • 26. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.
    Int J Gynecol Pathol; 2016 Jan 30; 35(1):48-55. PubMed ID: 26166714
    [Abstract] [Full Text] [Related]

  • 27. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E, Nout RA, Naves LC, Ter Haar NT, Creutzberg CL, Smit VT, Bosse T.
    Gynecol Oncol; 2014 May 30; 133(2):197-204. PubMed ID: 24556061
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N, Reis-Filho JS, Weigelt B.
    Gynecol Oncol; 2019 Jan 30; 152(1):11-19. PubMed ID: 30415991
    [Abstract] [Full Text] [Related]

  • 30. The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.
    Xiong J, He M, Hansen K, Jackson CL, Breese V, Quddus MR, Sung CJ, Lomme MM, Lawrence WD.
    Gynecol Oncol; 2016 Jul 30; 142(1):163-168. PubMed ID: 27154241
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ.
    Clin Cancer Res; 2005 Sep 15; 11(18):6422-30. PubMed ID: 16166416
    [Abstract] [Full Text] [Related]

  • 35. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC, Ubachs JEH, Stelloo E, de Kroon CD, Goeman JJ, Smit VTHBM, Creutzberg CL, Bosse T.
    Histopathology; 2018 Jan 15; 72(2):248-258. PubMed ID: 28795426
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
    Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, Moriuchi T.
    Gynecol Oncol; 2001 Dec 15; 83(3):485-90. PubMed ID: 11733960
    [Abstract] [Full Text] [Related]

  • 38. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I, De Leo A, D'Angelo E, Rosa-Rosa JM, Corominas M, Gonzalez A, Palacios J, Prat J.
    Hum Pathol; 2018 Feb 15; 72():100-106. PubMed ID: 29133142
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.